Unnatural Products, Inc. (UNP), a biotech developing orally-delivered macrocyclic peptides to address previously undruggable targets, today announced a research collaboration and licensing agreement with Novartis on an undisclosed program.
The collaboration brings together UNP’s AI-enhanced macrocycle platform and Novartis’ global development and commercialization capabilities to generate next-generation therapeutics with potential applications in the cardiovascular disease area. Novartis will assume responsibility for IND-enabling studies and all subsequent clinical development, manufacturing, and global commercialization of products emerging from the collaboration.
Macrocyclic peptides represent a powerful therapeutic class that merges the selectivity and potency of biologics with the flexibility and drug-like properties of small molecules, enabling access to previously undruggable targets. UNP’s integrated discovery engine combines AI-guided molecular design, massively parallel synthesis, and direct-to-biology screening to rapidly generate highly potent and selective macrocycles suited for both oral and injectable modalities.
“This collaboration validates the strength of our program and highlights the ability of UNP’s platform to deliver differentiated macrocyclic therapeutics for high-value biological targets for chronic diseases with high unmet need,” said Cameron Pye, Ph.D., CEO and Co-Founder, Unnatural Products. “Novartis has built a highly respected engine in cardiovascular innovation, and we are excited to collaborate with them to unlock the full therapeutic potential of this asset. Together, we have the opportunity to advance medicines that could meaningfully improve patient lives across various diseases.”
https://au.finance.yahoo.com/news/unnatural-products-announces-licensing-agreement-130000763.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.